Phosphodiesterase activity in intrapulmonary arteries and veins of perinatal lambs

Molecular Genetics and Metabolism

Volumn 65, Issue 3, 1998, Pages 229-237

  Okogbule Wonodi, A C ^a   Ibe, B O ^a   Yue, B W ^a   Hsu, S ^a   Raj, J U ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arteries; cAMP; cGMP; Pulmonary vascular tone; Rolipram; Veins; Zaprinast

Indexed keywords

CYCLIC AMP; CYCLIC GMP; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; ZAPRINAST;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; ENZYME ACTIVITY; ENZYME INHIBITION; FETUS; FETUS DEVELOPMENT; GESTATIONAL AGE; HYDROLYSIS; LAMB; LUNG BLOOD VESSEL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

ANIMALIA; OVIS ARIES;

EID: 0031646970     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1998.2756     Document Type: Article

References (33)

1. McDaniel N L, Rembold C M, Murphy R A. Cyclic nucleotide dependent relaxation of vascular smooth muscle. Can J Physiol Pharmacol. 72:1994;1380-1385.
2. Barnes P J. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J. 8:1995;457-462.
3. Thompson W J. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacol Ther. 51:1991;13-33.
4. Dent G, Magnussen H, Rabe K F. Cyclic nucleotide phosphodiesterases in the human lung. Lung. 172:1994;129-146.
5. Manganiello V, Murata T, Taira M, Belfrage P, Degerman E. Perspectives in biochemistry and biophysics. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys. 322:1995;1-13.
6. Nicholson C D, Challiss R A, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. Trends Pharmacol Sci. 12:1991;19-27.
7. Renowden S, Edwards D H, Griffith T M. Impaired cyclic nucleotide-mediated vasorelaxation may contribute to closure of human umbilical artery after birth. Br J Pharmacol. 106:1992;348-353.
8. Abman S H, Ivy D D, Ziegler J W, Kinsella J P. Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. J Perinatol. 16:1996;S18-23.
9. Ziegler J W, Ivy D D, Fox J J, Kinsella J P, Clarke W R, Abman S H. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol. 269:1995;H473-9.
10. Cohen A H, Hanson K, Morris K, Fouty B, McMurtry I F, Clarke W, Rodman D M. Inhibition of cyclic 3′5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 97:1996;172-179.
11. Bornfeldt K E. Intracellular signaling in arterial smooth muscle: Chemotaxis versus proliferation. Trends Cardiovasc Med. 6:1996;143-151.
12. Czarniecki M, Ahn H-S, Sybertz E J. Inhibitors of types I and V phosphodiesterase: Elevation of cGMP as a therapeutic strategy. Ann Rep Med Chem. 31:1996;61-79.
13. Toga H, Ibe B O, Raj J U. In vitro responses of ovine intrapulmonary arteries and veins to endothelin-1. Am J Physiol. 263:1992;L15-L21.
14. Kincaid R L, Manganiello V C. Assay of cyclic nucleotide phosphodiesterases using radiolabeled and fluorescent substrates. Methods Enzymol. 158:1988;457-466.
15. m. J Pharmacol Exp Ther. 247:1988;34-42.
16. Lowry H O, Resebrough N J, Farr A L, Randall R J. Protein measurement with folin phenol reagent. J Biol Chem. 193:1951;265-575.
17. Francis S H, Noblett B D, Todd B W, Wells J N, Corbin J D. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol Pharmacol. 34:1988;506-517.
18. Cobb C E, Beth A H, Corbin J D. Purification and characterization of an inactive form of cyclic AMP-dependent protein kinase containing bound cyclic AMP. J Biol Chem. 262:1987;16566-16574.
19. Papapetropoulos A, Marczin N, Mora G, Milici A, Murad F, Catravas J D. Regulation of vascular smooth muscle soluble guanylate cyclase activity, mRNA, and protein levels by cAMP-elevating agents. Hypertension. 26:1995;696-704.
20. Lincoln T M, Cornwell T L. Intracellular cyclic GMP receptor protein. FASEB J. 7:1993;328-338.
21. Ziegler J W, Ivy D D, Kinsella J P, Abman S H. The role of nitric oxide, endothelin, and prostaglandins in the transition of the pulmonary circulation. Clin Perinatol. 22:1995;387-403.
22. Hanson K A, Burns F, Rybalkin S D, Miller J W, Beavo J, Clarke W R. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein and message. Am J Respir Crit Care Med. 158:1998;279-288.
23. Gao Y, Zhou H, Raj J U. Heterogeneity in role of endothelium-derived NO in pulmonary arteries and veins of full-term fetal lambs. Am J Physiol. 268:1995;H1586-H1592.
24. Gao Y, Zhou H, Raj J U. Endothelium-derived nitric oxide plays a larger role in pulmonary veins than in arteries newborn lambs. Cir Res. 76:1995;559-565.
25. Delporte C, Poloczek P, Winard J. Role of phosphodiesterase II in cross talk between cGMP and cAMP in human neuroblastoma NB-OK-1 cells. Am J Physiol. 270:1996;C286-C292.
26. Mathew R, Wang J, Gewitz M H, Hintze T H, Wolin M S. Congestive heart failure alters receptor-mediated cAMP-mediated relaxation of canine pulmonary arteries. Circulation. 87:1993;1722-1728.
27. Jiang H, Colbran J L, Francis S H, Corbin J K. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem. 267:1992;1015-1019.
28. Cohen A H, Hanson K, Moris K, Fouty B, McMurtry I F, Clarke W, Rodman D M. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmoanry circulation in chronically hypoxic rats. J Clin Invest. 97:1996;172-179.
29. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilate porcine large coronary arteries. J Pharmacol Exp Ther. 272:1995;825-831.
30. Kashimura O, Sakai A. Lung cyclic nucleotides in exercise-trained rats attenuates hypoxic pulmonary vasoconstriction. Lung. 173:1995;363-372.
31. Braner D AV, Fineman R, Chang R, Soifer S J. M&B 22948, a cGMP phospodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol. 264:1993;H252-H258.
32. Ahn H S, Crim W, Pitts B, Sybertz E J. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases: Tissue distribution, drug sensitivity and regulation of cyclic GMP levels. Advances in Second Messenger and Phosphoprotein Research. 1992;Raven Press, New York. p. 271-288.
33. Clarke W R, Uezono S, Chambers A, Doepfner P. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol. 7:1994;81-89.